ATEC — Q2 2026 Financial Report Analysis

Spine surgery volumes up 20%, losses shrinking, but the cash cushion got thinner

Alphatec (ATEC) sells spinal implants, surgical instruments and the EOS imaging system that surgeons use to plan and check spine operations. In the second quarter of 2026 (April–June) revenue rose 15% to $213.5 million, driven by a 20% rise in the number of surgical cases using its products. The company still lost money under standard accounting (GAAP) — $25.8 million — but that loss was 37% smaller than a year ago, and the business came within $1.9 million of breaking even at the operating level. Management kept its full-year revenue forecast and raised its profit (adjusted EBITDA) forecast.

At a glance

• Revenue $213.5 million, +15%. Surgical revenue of about $196 million grew 17%; almost all of the growth came from more procedures, not higher prices.
• Operating loss $1.9 million vs $13.1 million a year ago. Operating margin — the share of revenue left after running the business, before interest and tax — improved from -7.1% to -0.9%, as gross margin rose 2.6 points and spending grew slower than sales.
• Free cash flow of roughly $0.6 million. Positive, as the company says, but only just; for the first half it was about -$10 million against a full-year target of at least +$20 million.

Results

For the first six months, revenue was $405.6 million (+14.3%) and the net loss was $59.7 million, down from $93.1 million.

What drove the quarter

Volume, not price. The 10-Q attributes the revenue increase "primarily" to higher product volume "due to the increase in our surgeon user base, continued expansion of our new product portfolio, and increasing adoption of our technology." Case volume grew 20% while surgical revenue grew 17%, which implies revenue per case slipped slightly — more procedures, each bringing in a little less on average. Net new surgeons using ATEC products rose 24%, the leading indicator for future case volume, and slightly faster than the 23% reported for the first quarter.

EOS imaging is the weak spot. The company does not break out EOS in the filing, but surgical revenue of about $196 million out of $213.5 million total leaves roughly $18 million for EOS — about flat on a year ago by the same arithmetic. In May, management cut its 2026 EOS forecast from $85 million to $77 million while keeping the surgical forecast at $805 million. Total company growth (15%) therefore trails surgical growth (17%).

Margins widened at both levels. Cost of sales rose only 5% against 15% revenue growth, lifting gross margin — revenue left after the direct cost of making and supplying the products — to 72.2% from 69.6%. Sales, general and administrative costs rose 13% ($15.5 million), which the 10-Q puts down to commissions and other costs that rise with revenue plus continued investment in ATEC's own distribution channel. Research and development was flat at $18.2 million. Spending growing slower than revenue is what moved operating margin up 6.2 points.

What the headline numbers hide

• The smaller net loss is partly a one-off swap. This quarter carries an $11.9 million loss on debt extinguishment (writing off costs when it repaid its old Braidwell term loan and MidCap credit line early). Last year's quarter carried a $16.8 million loss on a derivative tied to its convertible bonds. Stripping both out, the net loss improved from about $24.4 million to about $13.9 million — a real improvement, but smaller than the headline $15.4 million.
• Adjusted profit leaves out large recurring costs. Adjusted EBITDA of $36.0 million sits about $38 million above the GAAP operating loss. Most of the gap is depreciation and amortization ($19.8 million, much of it on surgical instrument sets the company lends to hospitals) and stock-based compensation ($18.1 million, 8.5% of revenue — employees paid in shares instead of cash). The company's "non-GAAP net income" of $11.4 million also excludes non-cash interest and applies a notional 26% tax rate. Both measures make ATEC look more profitable than the GAAP figures.
• Cash conversion is weak and inventory is the reason. Operating cash flow was $21.8 million for the first half against a $59.7 million net loss (non-cash charges explain the difference). But inventory consumed $34.0 million of cash in the first half versus $0.9 million a year earlier; the inventory balance rose 15% in six months to $194.9 million, as fast as a full year of revenue growth. A $18.3 million increase in money owed to suppliers offset about half of that. The company also wrote down $8.1 million of excess and obsolete inventory in the half.
• Free cash flow was barely positive. Using the company's own definition (operating cash flow minus capital spending), the quarter produced about +$0.6 million ($20.5 million operating cash flow less $19.9 million of equipment purchases, mostly surgical instruments). The first half was about -$10.2 million.
• Per-share figures are diluted by new shares. The weighted share count rose 4.5% to 156.6 million, so the per-share loss improved slightly less than the dollar loss.
• Balance sheet: after the quarter ended, $63.3 million of convertible notes were repaid in cash (on July 30, 2026), against $118.7 million of cash at June 30 — leaving roughly $55 million before third-quarter cash flow. The new JPMorgan-led bank facility (May 2026: a $175 million term loan plus a $125 million revolver, $40 million drawn) replaced costlier debt, and the company said it would cut interest expense by more than $6 million a year; cash interest already fell to $4.4 million from $5.3 million. Stockholders' equity turned slightly negative (-$12.1 million) and $405 million of 2030 convertible notes remain.

Guidance

The arithmetic of what's left: the $882 million revenue target requires about $476 million in the second half, about 16% above the $409 million of the second half of 2025 — a bit faster than the 14% achieved in the first half. The $140 million EBITDA target needs about $83 million in the second half (about a 17.5% margin, slightly above this quarter's 16.8%). The $20 million free cash flow target needs at least $30 million in the second half, after -$10 million in the first.

Takeaway: ATEC's surgical franchise is doing what management says — 20% more cases and 24% more new surgeons, with operating losses nearly gone — but the cash story lags the profit story. Inventory build and instrument spending absorbed almost all of the operating cash flow, so the year's ≥$20 million free cash flow goal now rests entirely on the second half, with a cash balance that dropped to about $55 million after repaying the 2026 notes.

Outlook

Management reaffirmed $882 million of revenue (about 15% growth, 17% surgical) and raised adjusted EBITDA guidance to about $140 million from $134 million, citing operating leverage. The surgical business is tracking that plan: 17% surgical growth in both quarters so far matches the full-year surgical target, and surgeon adoption is still accelerating slightly. The EBITDA raise looks achievable given the 4.2-point margin gain this quarter.

The point to watch is cash. The second half has to produce at least $30 million of free cash flow after two quarters that totalled about -$10 million, which depends on inventory growth slowing after the first-half build. A third quarter where inventory again grows faster than revenue would put the free cash flow target, and the company's still-thin cash cushion, under pressure. EOS also needs to stabilize near the reduced $77 million forecast; another cut would weigh on total growth even if surgical volumes hold. This is ATEC's first report on this site, so there is no earlier outlook to check against.